RETRACTED: Randomized Trial of Narrow-band Versus White-light Cystoscopy for Restaging (Second-look) Transurethral Resection of Bladder Tumors

Herr, Harry W.

doi:10.1016/j.eururo.2014.06.049

Cited by 37 publications

(36 citation statements)

References 8 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Herr and Donat also previously demonstrated in a nonrandomized fashion that NBI reduces recurrence specifically of lowrisk NMIBC [5]. In the current study, Herr has therefore attempted to demonstrate the benefit of NBI in high-risk NMIBC [1]. While the rationale for this attempt is not explicitly outlined in the paper, the analysis is justified by the increased risk of recurrence and progression in high-risk disease, as well as the different therapeutic interventions administered in this patient cohort.…”

mentioning

confidence: 76%

“…The trial demonstrated a reduction in rate of recurrence at 2 yr from 33% to 22% ( p = 0.05) but was underpowered to reach the desired 20% risk reduction [1]. Since the trial was performed in the setting of a second transurethral resection of bladder tumor (TURBT), 38% of patients had no disease in the pathologic specimen, which may have negatively affected the value of NBI.…”

mentioning

confidence: 96%

“…In this month's issue of European Urology, Herr reports on the largest prospective randomized trial to date investigating the clinical benefit of narrow-band imaging (NBI) in the management of non-muscle-invasive bladder cancer (NMIBC) [1]. Herr is to be congratulated for achieving this milestone and for doing so single-handedly in such precise fashion.…”

mentioning

confidence: 98%

See 2 more Smart Citations

RETRACTED: Narrowing the Cystoscopy Gap

Black

2015

European Urology

View full text Add to dashboard Cite

mentioning

confidence: 76%

mentioning

confidence: 96%

See 1 more Smart Citation

RETRACTED: Narrowing the Cystoscopy Gap

Black

2015

European Urology

View full text Add to dashboard Cite

“…[166][167][168][169] Similarly, several randomized trials have evaluated narrow band imaging (NBI) and demonstrated improved cancer detection rate compared to WLC. [170][171][172][173] Both NBI and PDD have shown increased tumour detection and decreased recurrences compared to WLC TUR. However, impact on long-term recurrences and progression has not been demonstrated.…”

Section: Discussionmentioning

confidence: 99%

Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015

Kassouf

Aprikian

Black

et al. 2016

CUAJ

View full text Add to dashboard Cite

This initiative was undertaken in response to concerns regarding the variation in management and in outcomes of patients with bladder cancer throughout centres and geographical areas in Canada. Population-based data have also revealed that real-life survival is lower than expected based on data from clinical trials and/or academic centres. To address these perceived shortcomings and attempt to streamline and unify treatment approaches to bladder cancer in Canada, a multidisciplinary panel of expert clinicians was convened last fall for a two-day working group consensus meeting. The panelists included urologic oncologists, medical oncologists, radiation oncologists, patient representatives, a genitourinary pathologist, and an enterostomal therapy nurse. The following recommendations and summaries of supporting evidence represent the results of the presentations, debates, and discussions. Methodology

show abstract

“…NBI cystoscopy has been shown to improve detection rates of bladder tumors [Cauberg et al 2010], and is associated with lower recurrence rates and longer recurrencefree survival (RFS) time [Herr et al 2011] than conventional WLC. A single-surgeon randomized study comparing 2-year RFS of patients with NMIBC using NBI or WLC showed that NBI cystoscopy improves completeness of bladder tumor resection, which reduces the frequency of early and late tumor recurrences [Herr, 2015].…”

Section: Discussionmentioning

confidence: 99%

Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder

Stasi

Carlo

Pagliarulo

et al. 2015

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Abstract:Clinical trials have shown that hexaminolevulinate (HAL) fluorescence cystoscopy improves the detection of bladder tumors compared with standard white-light cystoscopy, resulting in more efficacious treatment. However, some recent meta-analyses report controversially on recurrence-free rates with this procedure. A systematic review of literature was performed from December 2014 to January 2015 using the PubMed, Embase and Cochrane databases for controlled trials on photodynamic diagnosis (PDD) with HAL. A total of 154 publications were found up to January 2015. Three of the authors separately reviewed the records to evaluate eligibility and methodological quality of clinical trials. A total of 16 publications were considered eligible for analysis. HAL-PDD-guided cystoscopy increased overall tumor detection rate (proportion difference 19%, 95% confidence interval [CI] 0.152-0.236) although the benefit was particularly significant in patients with carcinoma in situ (CIS) lesion (proportion difference 15.7%, 95% CI 0.069-0.245) and was reduced in papillary lesions (Ta proportion difference 5.9%, 95% CI 0.014-0.103 and T1 proportion difference 1.2%, 95% CI 0.033-0.057). Moreover, there were 15% of patients (95% CI 0.098-0.211) with at least one additional tumor seen with PDD. With regard to recurrence rates, the data sample was insufficient for a statistical analysis, although the evaluation of raw data showed a trend in favor of HAL-PDD. This meta-analysis confirms the increased tumor detection rate by HAL-PDD with a most pronounced benefit for CIS lesion.

show abstract

RETRACTED: Randomized Trial of Narrow-band Versus White-light Cystoscopy for Restaging (Second-look) Transurethral Resection of Bladder Tumors

Cited by 37 publications

References 8 publications

RETRACTED: Narrowing the Cystoscopy Gap

RETRACTED: Narrowing the Cystoscopy Gap

Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015

Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder

Contact Info

Product

Resources

About